Status:
COMPLETED
Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
Lead Sponsor:
Outset Medical
Conditions:
End Stage Kidney Disease
End Stage Renal Disease
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
Eligibility Criteria
Inclusion
- Participant is 18 years of age.
- Participant weighs ≥ 34kg.
- Participant was hospitalized and had dialysis dependent End-Stage Renal Disease or Acute Kidney Injury and was prescribed acute intermittent renal replacement therapy.
Exclusion
- Treatments isolated to ultrafiltration only.
- Any documented condition the Physician feels would prevent the participant from successful inclusion in the study.
Key Trial Info
Start Date :
May 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 15 2022
Estimated Enrollment :
458 Patients enrolled
Trial Details
Trial ID
NCT04912024
Start Date
May 15 2021
End Date
June 15 2022
Last Update
August 12 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Adventist Health System
Orlando, Florida, United States, 32803
2
Texas Health Harris Methodist Hospital Fort Worth
Fort Worth, Texas, United States, 76104